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Effect on walking distance and atherosclerosis
progression of a nitric oxide-donating agent in
intermittent claudication
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Pietro Minuz, MD,e and Francesco Violi, MD,f on behalf of the NCX 4016-X-208 Study
Group,* Perugia, Cortona, Verona, Milan, and Rome, Italy
Background: Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involve-
ment of the arterial tree and endothelial dysfunction. Previous short-term studies showed improvement of vascular
reactivity and walking capacity in PAD patients by measures aimed at restoring nitric oxide (NO) production. NO is also
known to prevent the progression of atherosclerosis. We wished to assess whether the prolonged administration of an
NO-donating agent (NCX 4016) improves the functional capacity of PAD patients and affects the progression of
atherosclerosis as assessed by carotid intima-media thickness (IMT).
Methods: This prospective, double-blind, placebo-controlled study enrolled 442 patients with stable intermittent
claudication who were randomized to NCX 4016 (800 mg, twice daily) or its placebo for 6 months. The primary study
outcome was the absolute claudication distance on a constant treadmill test (10% incline, 3 km/h). The main secondary
end point was the change of the mean far-wall right common carotid artery IMT.
Results: The increase of absolute claudication distance at 6 months compared with baseline was 126  140 meters in the
placebo-treated group and 117  137 meters in the NCX 4016-treated group, with no significant differences. Carotid
IMT increased in the placebo-treated group (0.01 0.01 mm; P .55) and decreased in the NCX 4016-treated group
(0.03  0.01 mm; P  .0306). Other secondary end points did not differ between the two treatments.
Conclusions: Long-term NO donation does not improve the claudication distance but does reduce progression of
atherosclerosis in patients with PAD. Further studies aimed at assessing whether long-term NO donation may prevent
ischemic cardiovascular events are warranted. (J Vasc Surg 2012;56:1622-8.)
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CPeripheral arterial disease (PAD) is a condition of leg
ischemia caused by atherosclerosis of the arteries of the
lower limbs.1,2 An early symptom of PAD is intermittent
claudication, a disabling pain on walking that can be
relieved by rest and that is caused by muscular ischemia,
immediately followed by reperfusion during rest. PAD is
caused by atherosclerosis, but dysfunction of the endo-
thelium in the lower limbs may also contribute to the
development of symptoms by reducing the ability of the
arteries to supply muscles with the required quantity of
oxygen during exercise. In later stages, progression of
atherosclerosis of the lower limb arteries can lead to
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1622schemic pain at rest, ulceration, gangrene, and in some
ases, limb amputation.
PAD is almost invariably associated with a generalized
therosclerotic involvement of the arterial tree and is fre-
uently associated with clinical ischemia of the coronary
nd cerebrovascular circulation. Endothelial dysfunction
as been shown to play a role in the initial phases of the
therosclerotic process and in the precipitation of ischemic
vents3 and is mainly attributable to the loss of the capacity
f the endothelium to produce nitric oxide (NO).
Endothelial dysfunction is the consequence of the nox-
ous effects of several classical and novel risk factors on the
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Volume 56, Number 6 Gresele et al 1623endothelium.3,4 However, ischemia-reperfusion damage
also contributes to endothelial dysfunction and to the
progression of systemic atherosclerotic disease by provok-
ing an inflammatory reaction in the involved tissue and a
systemic response with activation of circulating neutro-
phils, increase of endothelial adhesion molecules, and re-
lease of several cytokines.5-7
It has thus been hypothesized that therapeutic inter-
ventions aimed at restoring NO levels, by favoring endog-
enous NO biosynthesis or by supplying exogenous NO,
may be beneficial to the functional capacity and to the
systemic progression of atherosclerotic disease in patients
with PAD. The positive effect shown by the long-term
administration of some statins, such as simvastatin or ator-
vastatin,8-10 has been interpreted as partly due to the ability
to restore the production of NO.11
Another example of such an approach has been the oral
supplementation with large doses of L-arginine, the meta-
bolic precursor of NO. Short-term administration has
shown very promising activity on the functional capacity of
patients with PAD, with a striking increase in the claudica-
tion distance.12 Moreover, several preclinical studies
showed that long-term supplementation with L-arginine
inhibited atherosclerosis and myointimal hyperplasia and
enhanced angiogenesis.13 On the basis of these premises, a
long-term clinical trial testing long-term L-arginine admin-
istration to PAD patients was performed, but with disap-
pointing results: NO synthesis and vascular reactivity were
not improved.14
An alternative approach is that of directly providing
NO using an NO-donating agent. Indeed, treatment with
S-nitroso albumin protected skeletal muscle from ischemia-
reperfusion injury in rabbits,15 and some nitrates were
shown to prevent endothelial dysfunction induced by
ischemia-reperfusion in humans.16 Moreover, sublingual
glyceryl trinitrate improved the maximum walking capacity
of patients with intermittent claudication.17 In addition,
transdermal nitroglycerin was shown to decrease inflamma-
tory mediators in patients with PAD,18 suggesting a possi-
ble protective role on atherosclerosis progression.
NCX 4016, an NO-releasing derivative of acetylsali-
cylic acid able to produce a sustained release of low concen-
trations of NO in vivo, demonstrated remarkable antiath-
erosclerotic activity in several preclinical models.19,20 We
previously showed that a 4-week administration of NCX
4016 to patients with intermittent claudication prevented
the acute endothelial dysfunction induced by exercise and
produced an increase, although not significant, of the initial
claudication distance (ICD).7 Moreover, recent data have
shown beneficial effects of the administration of NCX 4016
to patients with type 2 diabetes mellitus, a frequent risk
factor in PAD patients, in terms of inhibition of platelet
function and metabolic control.21,22 It thus seemed logical
to test whether long-term NO donation with NCX 4016
improves the claudication distance in an appropriately sized
clinical trial in patients with intermittent claudication. An-
other aim of our study was to assess the effects of prolonged
NO treatment on atherosclerosis progression as docu- [ented by the measurement of intima-media thickness
IMT) at the level of the common carotid artery.23
ETHODS
Design of the study. This was a prospective, random-
zed, double-blind, parallel-groups, placebo-controlled
tudy conducted in 43 clinical sites throughout Europe. A
otal of 442 patients with PAD at Leriche-Fontaine stage II
ere treated for 6 months with NCX 4016 (800 mg, twice
aily) or with an indistinguishable placebo. The twice-daily
osage of 800 mg was selected based on previous clinical
tudies that demonstrated a good safety profile and a good
olerability in the gastrointestinal tract.19 Compliance was
hecked by counting dispensed vs returned study medica-
ion. Participants were allocated to treatment according to
centrally generated randomization list, balanced for each
articipating center. Inclusion criteria are reported in the
upplemental Methods (online only).
All patients received aspirin (100 mg, once daily) for
ardiovascular prevention, which was standard for this pa-
ient population at the time of study design.1,2
The primary end point of the study was the absolute
laudication distance (ACD) on a constant treadmill test.
econdary end points were evaluations at 6months of ICD,
he proportion of patients showing a 28% or a 50%
mprovement of ACD,24,25 quality of life as assessed by the
hort Form 36 Health Survey,26 variations of the ankle-
rachial index (ABI), and modifications of the IMT of the
ight common carotid artery. Details on IMTmeasurement
re reported in the Supplemental Methods (online only).
Statistical methods. The primary study objective was
o demonstrate a clinically significant difference in the ACD
etween active treatment and placebo after 6 months of
herapy. For this purpose, ACD data were fitted by a
eneralized linear model with log-link function and assum-
ng -distribution of errors. Treatment, centers (dummy
ovariates), and log-transformed run-in ACD values (con-
inuous covariate) were considered as the independent
ariables of the model. Results are reported as model-based
stimates of treatment differences with associated two-
ided 95% confidence limits. A further ad hoc analysis based
n ACD data transformed into ranks (nonparametric ap-
roach) was used to assess the sensitivity of the analysis to
he assumed model (-distribution). Sample size calcula-
ion and other details on statistical analysis are available in
he Supplemental Methods (online only).
The trial was registered at http://ClinicalTrials.gov
NCT01256775).
ESULTS
Demographics and baseline characteristics. A total
f 442 patients, who met the inclusion and exclusion
riteria, were enrolled in the trial in 43 centers from five
uropean countries and were randomly allocated to either
f the two treatment groups; 372 of 442 patients (84%)
ompleted the study (Fig 1). Of the 70 patients who
ropped out (44 [19.9%] in the NCX 4016 group and 26
11.8%] in the placebo group), reasons for discontinuation
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December 20121624 Gresele et alwere adverse events (25 in the NCX 4016 group, nine in
the placebo group); protocol violation (three in the NCX
4016 group and five in the placebo group); patient with-
drawal of consent (11 in the NCX 4016 group and 10 in
the placebo group); and other reasons (five in the NCX
4016 group and two in the placebo group).
No relevant heterogeneity among the two study groups
was found in demographic variables (Table I). As expected,
most patients were men (80.1% on NCX 4016, 78.3% on
placebo), and mean age was 66.7  8.2 (NCX 4016) and
66.4  9.1 years (placebo). In the entire cohort, the most
prevalent risk factor was hypertension (69.0%), followed by
dyslipidemia (56.3%) and diabetes (32.5%). In the NCX
4016 and placebo groups, respectively, the mean ABI was
0.66  0.15 and 0.64 0.15, mean baseline ACD was
210 107 and 214114 meters, and mean baseline ICD
was 131.5 77 and 131 78 meters, respectively. Con-
cerning concomitant medications, 52.2% of patients were
taking statins, with a significant imbalance in favor of the
NCX 4016 group (57.9% vs 46.6%; P .0173), and 41.4%
were taking angiotensin-converting enzyme inhibitors
(ACE-Is)/angiotensin receptor blockers (ARBs), with no
significant differences between the two groups.
Effects on the walking capacity and health-related
quality of life. The ACD increased in both treatment
groups from baseline to day 90 and continued to increase
from day 90 to day 180 (Fig 2). The increase of ACD at 6
months compared with baseline was126 140meters in
the placebo group and 117  137 meters in the NCX
4016 group. In the intention-to-treat analysis, the differ-
Fig 1. Flow chart of the trial profile.ence in ACD from baseline to day 180 between NCX v016-treated and placebo-treated patients was not signifi-
ant (4.6%; range, 3.5% to 13.4%; P  .27). The
n-treatment analysis also showed no significant difference
n the primary end point between the two study groups
6.5%; range, 3.1 to 16.9; P  .1927). There was no
nteraction of the primary end point with other background
Intention to treat; OT, on-treatment.
able I. Demographic characteristics of patients in the
wo study groups
ariablea NCX 4016 Placebo P
ge, years 66.7  8.2 66.4  9.1 .6839
ex
Female 44 48
Male 221 221 .6393
AD duration, years 5.61  4.87 5.35  4.89 .5906
ody mass index, kg/m2 26.6  4.3 26.6  4.2 .9512
ypertension 154 (69.7) 151 (68.3) .7577
yslipidemia 133 (60.2) 116 (52.5) .1030
iabetes 77 (34.8) 67 (30.3) .3102
urrent cigarette smoker 91 (41.2) 91 (41.2) .3243
edication use
Statin 128 (57.9) 103 (46.6) .0173
ACE-I 99 (44.8) 84 (38.0) .1475
ARB 54 (24.4) 44 (19.9) .2522
BI 0.66  0.15 0.64  0.15 .2444
CD, meters 210  107 217  114 .4896
CD, meters 131  77 131  78 .9959
BI, Ankle-brachial index; ACD, absolute claudication distance; ACE-I,
ngiotensin-converting enzyme inhibitor;ARB, angiotensin receptor block-
r; ICD, initial claudication distance; PAD, peripheral arterial disease.
Continuous data are shown as the mean standard deviation and categoric
ata as number (%).ariables, such as hypertension, smoking, dyslipidemia, or
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Volume 56, Number 6 Gresele et al 1625concomitant drug use. In a post hoc subgroup analysis in
77 diabetic patients in the NCX 4016 group and 67 in the
placebo group, the difference in ACD from baseline to 6
months was significantly higher in the NCX 4016 group
than in the placebo group (15.2%; range, 0.9%-31.5%;
P  .0376). Concerning secondary end points, the ICD
increased by 84.5  88.5 meters in the placebo group and
by 84.3  100.2 meters in the NCX 4016 group. The
difference in ICD at day 180 between NCX 4016 patients
and placebo patients was not significant (5.9%; range,
2.7%-15.1%; P .1838). The proportion of patients with a
28% improvement in ACD at 6 months compared with
baseline was 44.3% in the NCX 4016 group and 44.8% in
the placebo group (P .9238). The proportion of patients
with a 50% improvement in ACD at 6 months compared
with baseline was 34.4% in the NCX 4016 group and 30.8%
in the placebo group (P  .4168). No statistically signifi-
cant difference between the two groups was found for any
of the Short Form 36-related parameters (Table II).
Effects on the progression of atherosclerosis. The
ABI was measured at run-in to verify patient eligibility at
baseline and at completion of the 6-month treatment pe-
riod. The ABI of the most affected limb remained stable
throughout the study and did not differ between the pla-
cebo group (0.66  0.15) and NCX 4016 group (0.67 
0.16) at 6 months. No statistically significant difference
between NCX 4016 and placebo treatment was found for
changes of ABI between baseline and 6 months.
The common carotid IMT was measured at baseline
and at 180 days. A complete set of analyzable IMT data
was available from 183 patients (80 NCX 4016 patients
and 103 placebo patients). Some of the participating
centers did not have the technical means for image
acquisition, and several recordings were excluded from
Fig 2. Evolution of the absolute claudication distance (ACD)
during the trial in patients treated with NCX 4016 or placebo.
Data are shown as geometric means standard deviation and refer
to the intima-media thickness (IMT) analysis.the analysis for poor technical quality. tThe subgroup of patients for which IMT measure-
ents were available did not differ from the remaining
opulation for any demographic variable or for ACD. Base-
ine IMT did not differ significantly between the two treat-
ent groups (Supplemental Table I, online only). Mean
MT decreased from baseline to 6 months in the NCX
016-treated group (0.03  0.01; range, 0.06-0 mm;
 .0306) but increased in the placebo-treated group
0.01 0.01; range,0.01 to 0.01 mm; P .55; Fig 3).
he number of patients taking a statin in the two treatment
roups was balanced (NCX 4016, 46; placebo, 48; 2 
.141; P .1797). An analysis of IMT changes at 6months
n the subgroup taking statins confirmed a decrease of IMT
n theNCX 4016 group (0.04 0.18mm) and not in the
lacebo group (0.02  0.16 mm).
Adverse events. Adverse events occurred in 90 pa-
able II. Walking capacity and health-related quality of
ife (secondary end points) according to intention to treat
nalysisa
ariable NCX 4016 Placebo P
CD
atients with
28% improvement 98 (44.3) 99 (44.6) .9237
50% improvement 76 (34.4) 68 (30.8) .4168
OL score
Physical functioning
6 months-baseline 3.14  14.03 5.66  14.71 .1160
CD, meters
Baseline 131.5  77.3 131.5  78 .9959
6 months 203.0  162.6 193.2  138.8 .1838
BI
6 months-baseline 0.0  0.08 0.02  0.1 .1376
BI, Ankle-brachial index; ACD, absolute claudication distance; ICD,
nitial claudication distance; PAD, peripheral arterial disease; QOL, quality
f life.
Categoric data shown as number (%); continuous data shown as mean 
tandard deviation.
ig 3. Change from baseline in the mean intima-media thickness
IMT) of the right common carotid artery after 6months of treatment
ith either NCX 4016 or placebo. Data represent means standard
eviation. *P .0306 vs baseline.ients (40.7%) treated with NCX 4016 and in 69 (31.2%)
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December 20121626 Gresele et altreated with placebo (P  .0374; Supplemental Table II,
online only). The most frequent adverse event described in
the NCX 4016 group was diarrhea (11.3%), followed by
low back pain (2.3%) and epigastric discomfort (1.8%). A
significant difference was found between the two groups
with regard to diarrhea (25 patients in the NCX 4016
group and five in the placebo group; P  .05). A higher
number of patients discontinued the study drug in the
NCX 4016 group. Overall, 35 NCX 4016 patients com-
pared with 11 placebo patients interrupted the study drug
due to side effects (P .0002); in most cases, drug discon-
tinuation was the consequence of diarrhea.
In the placebo group, the most frequent adverse events
reported were diarrhea (2.26%), low back pain and limb pain,
and bronchitis and gastroesophageal reflux (for all, 2.26%).
Major cardiovascular events occurred in four patients in
the placebo group (one patient each with acute myocardial
infarction, angina, worsening of claudication, and sudden
death) and in six in the NCX 4016 group (three acute
myocardial infarctions, one angina, and two with worsen-
ing of claudication; P  NS).
DISCUSSION
The main finding of the present study is that 6 months of
administration of an oral NO-donating agent (NCX 4016)
does not improve the maximal walking distance in patients
with PAD compared with placebo. The study rationale was
based on the observation that patients with PAD have endo-
thelial dysfunction with impaired NO production,4,7 which is
partly the consequence of repeated ischemia-reperfusion in-
sults occurring during daily life in these patients; therefore, we
hypothesized that an NO-donor, by providing the missing
NO, would improve calf blood flow and functional capacity.
In agreement with this, a previous study showed that NCX
4016 administered for 1 month to PAD patients prevented
the acute endothelial dysfunction produced by maximal leg
exercise.7 Indeed, the administration to healthy volunteers of
L-arginine, the metabolic precursor of NO, protects from
endothelial dysfunction induced by ischemia-reperfusion.27
In addition, previous small studies with other NO donors,
such as nitroglycerin orwith theNOprecursor L-arginine, had
shown an improvement of the claudication distance in
PAD.12,17
The lack of an effect of NCX 4016 in the present
long-term clinical trial, despite effective NO release in
vivo,7,21 suggests that long-term NO donation is not able
to improve the functional capacity of PAD patients. This
finding is in agreement with a recent study showing that the
long-term supplementation with L-arginine, a precursor of
NO synthesis, is of no benefit in patients with intermittent
claudication.14 Development of tolerance to NO might be
one possible explanation of the lack of efficacy of NCX
4016 on the claudication distance, although this seems
unlikely, because a 4-week administration of this drug in a
previous study did not lead to the worsening of endothelial
function, a marker of development of tolerance.7 There-
fore, the findings of the present study, together with previ-
ous data with L-arginine administration, suggest that the Increase of NO to levels not inducing vasodilatory side
ffects may not be sufficient to significantly improve blood
ow to the exercising muscles.
However, despite the lack of effects on the claudication
istance, treatment with NCX 4016 inhibited significantly
he progression of carotid IMT, an established surrogate
arker of cardiovascular events in patients with atheroscle-
osis.23,28 In fact, although a slight increase of carotid IMT
as observed in the placebo-treated group at 6 months, a
lear and significant decrease was evident in the NCX
016-treated group.
Several previous studies with therapeutic agents of proven
fficacy in preventing atherosclerotic cardiovascular events,
uch as statins, ACE-Is, or ARBs, have shown a limiting effect
n the progression of IMT in patients with cardiovascular risk
actors.29-31Moreover, cilostazol, an antiplatelet agent able to
nhibit smoothmuscle cell proliferation and prevent restenosis
fter endovascular treatment of patients with femoropopliteal
therosclerotic lesions,32 was recently shown to induce regres-
ion of carotid atherosclerosis in patients with type 2 diabetes
ellitus during a 2-year observation period33 to an extent
imilar to that observed in the present study with NCX 4016.
he reduction of IMT in the NCX 4016 group in our study
as also similar in size to that observed with a 6-month
reatment period with pioglitazone in patients with type 2
iabetes mellitus.34
The effect of treatment on the progression of IMT was
prespecified end point of our study, although a secondary
nd point, and although this was determined in a subgroup
f the entire study population, this subgroup was rather
arge (183 patients) and not dissimilar in size to that of
reviously published clinical trials that had IMT as the
rincipal end point.30,34 In a subgroup analysis, statin
reatment did not affect the result of NCX 4016 treatment
n carotid IMT. This finding therefore suggests that NCX
016 exerts an antiatherosclerotic activity in aspirin-treated
atients at cardiovascular risk, even when added to a full set
f drugs active in preventing atherosclerosis progression,
uch as statins, ACE-Is, or ARBs. This finding is interesting
n view of the recent report that IMT progression is corre-
ated with the long-term incidence of ischemic cardiovas-
ular events in particular in patients with PAD.35
The reduction in the progression of atherosclerosis
roduced by NCX 4016 in our trial is in accordance with
everal preclinical studies showing an antiatherosclerotic
ffect of this NO donor in different models of atheroscle-
osis.20,36,37 Moreover, one large, community-based co-
ort study in young adults showed a significant correlation
etween the degree of endothelial dysfunction and IMT,
onfirming that an impaired capacity of the endothelium to
roduce NO contributes to the progression of atheroscle-
osis.38 We previously showed that oral administration of
CX 4016 to diabetic or PAD patients at the doses used in
he present trial significantly enhanced plasma levels of NO
egradation production.7,19,21 Altogether, these data suggest
hat the long-term supply of NOmay slow the progression of
therosclerosis. However, that the effect of NCX 4016 on
MTmay be partly unrelated to NO cannot be excluded.
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the two treatment groups is not in contrast with this
conclusion. In fact, significant ABI changes may be de-
tected only over longer observation periods and for much
more extensive progressions of atherosclerosis.
In the subgroup of patients with diabetes (	30% of the
study population), a statistically significant improvement of
ACD was seen in the NCX 4016 group compared with
placebo (15.2%; P  .038). Although this finding is not
fully explained, recent data showing that NCX 4016 stim-
ulates glucose transport in adipocytes without negatively
affecting insulin sensitivity, thus possibly helping in better
controlling glycemia,22 and that it controls hyperglycemia-
induced platelet activation better than aspirin,21 suggest a
preferential effect of NCX 4016 in diabetic individuals. Of
course, the hypothesis that the difference in ACD in the
diabetic subgroup may be due to the play of chance cannot
be excluded.
In terms of safety, NCX 4016 did not provoke hypo-
tension or any other detrimental action to the cardiovascu-
lar system. However, a significantly higher incidence of
episodic diarrhea was observed in the NCX 4016 group.
This side effect has previously been reported for cilostazol,
a phosphodiesterase inhibitor, and may be due to an in-
crease of cyclic guanosine monophosphate in the gut with
consequent water influx.39
Our study has several limitations. The ACD and ICD
data showed a large variability, suggesting that the severity
of the PAD in the patients enrolled was rather heteroge-
neous: this may have been partly responsible for the lack of
efficacy of NCX 4016 on the claudication distance; how-
ever, the claudication distance, as measured by a standard-
ized treadmill test, is an end point with an inherent large
variability.
A second limitation may be represented by the preva-
lence of treatment with statins or ACE-Is, or both, at lower
than current recommended standards; however, several
large registries of patients with PAD confirm that this
patient population is generally undertreated.40
Another limitation may be that the population for the
IMT substudy was not large; however, many previous studies
on the effect of agents active in preventing cardiovascular
events on the progression of IMTwere of a similar size. There
also may have been errors in IMTmeasurements due to poor
reproducibility at the participating centers or to intersonogra-
pher differences between scans performed at many different
institutions. However, the same expert sonographer ex-
amined each patient in our study with an identical ultra-
sound protocol throughout all the visits. The readings of
the recordings were centrally performed in random order
by a single expert investigator, unaware of the clinical
characteristics of the participants or of the treatment
groups, using automated digital edge-detection technol-
ogy, as indicated by the Mannheim carotid IMT consen-
sus.41 The striking stability of the values observed at 6
months in the placebo group is a further confirmation of
the good reproducibility of IMT measurements.ONCLUSIONS
Long-term NO donation does not increase functional
apacity in PAD patients, in accordance with previous data
n the lack of efficacy of 6 months of treatment with
-arginine,14 but does reduce atherosclerosis progression,
s shown by a significant reduction of carotid IMT. NCX
016 presents several peculiarities compared with previous
O donors, such as slow and sustained NO donation, the
bility to prevent the activation of platelets induced by a
ide range of agonists, the ability to prevent smooth mus-
le cell proliferation, and the capacity to induce reparative
eoangiogenesis in a mouse model of peripheral isch-
mia.19,21,37,42 However, NCX 4016 is poorly absorbed
nd has formulary limitations that have led to the interrup-
ion of its clinical development.21 Novel NO-donating
olecules with a better bioavailability and pharmacokinetic
rofile may represent ideal candidates for the treatment of
atients with atherosclerotic cardiovascular disease. Confir-
atory studies on the effect of orally active, slow-release
O donors on carotid IMT progression are warranted.
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Supplemental Methods
Inclusion criteria. Inclusion criteria were: male and
female patients between 40 and 80 years with Leriche-
Fontaine stage II PAD presenting symptoms of intermit-
tent claudication stable for at least 6 months, an ankle/
brachial index 0.9, an absolute claudication distance
(ACD) 500 m and an initial claudication distance (ICD)
50 m on a standardized treadmill test (10% incline, 3
km/hr), and clinical stability before inclusion (ie, changes
in ACD not exceeding 25% in two standardized treadmill
tests during run-in). All patients gave their written in-
formed consent.
Exclusion criteria were: unstable symptoms and/or
rapid deterioration of PAD during the previous 3 months;
presence of clinically significant renal or hepatic failure, or
insulin-dependent type 1 diabetes; uncontrolled type 2
diabetes, arterial hypertension, or dyslipidemia; any clinical
condition limiting the patient’s exercise ability (angina
pectoris, congestive heart failure, respiratory disease, bone
and joint disease, neurological disorders); active peptic
ulcer during the previous 6 months; any hemorrhagic con-
dition or history of bleeding; acute coronary syndrome or
acute cerebrovascular episodes during the previous 6
months; previous revascularization procedures during the
last 6 months or indication for vascular surgery; ischemic
rest pain; life expectancy 12 months; pregnancy or lacta-
tion; participation to other investigational trials within 3
months prior to inclusion; history of hypersensitivity or any
form of allergic reaction or contraindications to NSAIDs,
aspirin, and NO-donating drugs. The following treatments
were not allowed for the period of the study: continuative
use (7 days) of NSAIDs or nitrovasodilating drugs; phos-
phodiesterase type 5 inhibitors, anticoagulants, heparin,
ticlopidine, clopidogrel, indobufen, defibrotide, mesogly-
can, picotamide, pentoxyfylline, carnitine, sulodexide. All
other concomitant treatments were kept constant as much
as possible during the study period.
IMTmeasurement. Common right carotid artery was
examined by B-mode ultrasound in the longitudinal view,
1-1.5 cm proximally to the bifurcation. The measurement
of IMT was obtained according to the Mannheim carotid
intima-media thickness consensus (1) with one modifica-
tion: instead of acquiring the vascular wall image only with
the lateral probe incidence, images were acquired also with
the anterior and posterior incidence, in order to obtain
a triplicate number of measurements to be used for com-
parisons. Each position was visualized and recorded for at
least 15 sec. with simultaneous taking of the ECG tracing.
Images of the far wall of the distal 1 cm of the right
common carotid artery were obtained. IMT was calculated
from each of the three projections and the final value was
calculated from the average of all measurements. The base-
line carotid ultrasonographic examinations were used to
localize the site of interest at follow-up. Digitized still
images from an electrocardiographically defined diastolic
frame were analyzed offline. A single observer who was dnaware of the treatment assignments and the identities of
he patients measured the mean carotid intima media thick-
ess. Focal atherosclerotic plaques were excluded from the
easurements. All measurements were performed with the
se of an automated border detection system. A number of
easurements not inferior to 30 for each of the three image
cquisition incidences was carried out in the 1-cm segment
f the carotid artery assessed. For each subject the same
ltrasound system and transducer and the same operator
ere used throughout the study. Images were centrally
nalyzed at the coordinating center by a dedicated, auto-
ated computerized edge detection system for the mea-
urement of common carotid far wall intima-media using
he software M’ATH 2.0 (Metris Argenteuil, France).
Statistical methods. Analyses were performed both
n the full (intention-to-treat) and on the compliant (on-
reatment) analysis set. The full analysis set contained all
atients having received at least one dose of the random-
zed treatments; the compliant analysis set was a subset of
he full analysis set obtained by excluding patients with less
han 80% intake of the investigational drugs and/or amajor
rotocol deviation. Being a superiority trial, the results
btained from the analysis on the intention-to-treat popu-
ation were considered as primary end point, while the
n-treatment population was analyzed with the aim of
nsuring that protocol violations/deviations and drop-outs
r withdrawals did not affect the results. All computations
ere carried-out with the SAS version 8.2. Baseline charac-
eristics in the two study groups were compared by Student
-test or Mann-Whitney test. Assuming as clinically signif-
cant a 28% ACD increase in the active treatment group as
ompared with the placebo, using the basic methodology
or testing hypotheses about the means of two exponential
istributions (distance to event data), a total sample size of
20 patients, randomized according to 1:1 allocation ratio,
ould provide a 80% power to detect a ratio of 1.28 in
ean ACD between active treatment and placebo. There-
ore, 210 evaluable patients per treatment group were
equired.
Computations were carried out assuming a 0.05 signif-
cance level (alpha) and using a one-sided hypothesis based
n the F distribution. The PASS 2002® software was used
or sample size calculation.
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PPENDIX B
Study participants. Italy: (Anagni) Presidio Os-
edalieri di Anagni, P. Mollo; (Bari) Istituto di Malattie
ell’Apparato Cardiovascolare, Dipartimento di Metod-
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dell’Università degli Studi di Bari, M.M. Ciccone; (Bibbi-
ena) Presidio Ospedalieri del Casentino, G. Parca; (Bolo-
gna) U.O. Angiologia, G. Palareti; Servizio Angiologia e
Day Hospital Angiologico, G. Scondotto; (Bolzano) Os-
pedale Centrale di Bolzano San Maurizio, M. Marchesi; C.
Wiedermann; (Castelfranco Veneto) Presidio Ospedali-
ero di Castelfranco Veneto, U.O. di Medicina Generale –
Servizio Angiologia, A. Visonà; (Catania) U.O. Complessa
di Angiologia, Azienda Ospedaliera Vittorio Emanuele-
Ferrarotto-Santo Bambino c/o Presidio Ospedaliero Fer-
rarotto, M. Di Salvo; Angiologia Medica e Emoreologia,
Azienda Ospedalieria Garibaldi, S.S. Signorelli; (Catan-
zaro) U.O. Malattie Cardiovascolari, Azienda Ospedaliera
Mater Domini, F. Perticone; (Cortona) U.O. di Medicina
Interna, Ospedale di Cortona, R. Migliacci. (Ferrara) Isti-
tuto di Chirurgia Generale, Ospedale S. Anna, P. Zamboni;
(Foligno) U.O. Angiologia, Ospedale San Giovanni Bat-
tista, F.O. Flamini; (Gubbio) Presidio Ospedaliero di Gub-
bio, Medicina Generale, P. Parise; (Milano) Centro di
Ricerca Malattie Vascolari, Ospedale Luigi Sacco, M. Cata-
lano; (Napoli) Facoltà di Medicina e Chirurgia, Diparti-
mento di Medicina Clinica e Scienze Cardiovascolari e
Immunologiche, G. Brevetti; (Padova) U.O. di Angiolo-
gia, Ospedale di Padova, GM. Andreozzi; (Palermo)Dipar-
timento di Medicina Clinica e delle Patologie Emergenti-
Facoltà di Medicina e Chirurgia, Università di Palermo, S.
Novo; (Perugia) Dipartimento di Medicina Interna, Sezi-
one di Medicina Interna e Cardiovascolare, Università di
Perugia, P. Gresele; (Pescia) Ospedale Pescia Sezione Ag-
gregata Angiologia Medica, F. Lucarelli, G. Panigada; IPisa) Dipartimento di Medicina Interna, Università di
isa, M. Rossi; (Reggio Emilia) U.O. Angiologia Medica,
spedale Santa Maria Nuova, A. Ghirarduzzi; (Roma)
ervizio di Angiologia, Ospedale Sant’Eugenio, E. Marchi-
elli; Chirurgia Vascolare, Università la Sapienza, E. Sbara-
lia; U.O. Angiologia, Azienda Ospedaliera San Camillo-
orlanini, AR. Todini; Divisione di IV Clinica Medica,
oliclinico Umberto I-Università la Sapienza, F. Violi;
Siena) Dipartimento di Medicina Interna Cardiovascolare
Geriatria, Università di Siena, Policlinico le Scotte, S.
orconi; Istituto di Medicina Interna, Università di Siena,
oliclinico le Scotte, R. Nuti; (Venezia) U.O. Medicina
enerale I, Ospedale Civile SS Giovanni e Paolo, G. Am-
rosio; (Verona) Ospedale di Valeggio sul Mincio, E. Aro-
io.Austria: (Wien) DivisionOf Angiology, Department of
nternal Medicine II, Vienna University, E. Minar; Ha-
ushkrankenhaus Angiologishe Abteilung und Tageklinik,
. Hirschl; Vascular Outpatient Department, 1st Depart-
ent of Surgery, Lainz Hospital, A. Stumpflen. Belgium:
Leuven) Interne Geneeskunde/Bloedings en Vaatziekten,
Z Gasthuisberg, R. Verhaeghe. Germany: (Karlsbad)
linikum Karlsbad-Langensteinbach gGmbH, Gutt-
annstrasse 1, C. Diehm; (Hamburg) AG Klinische Phar-
akologie, Institute für Experimentelle und Klinische
harmakologie, Universitätsklinikum Hamburg-Eppen-
orf, R. Boeger. Switzerland: (Lausanne) Hospital Chuv,
. Hayoz.
Clinical trial statistician. Dr E. Bonizzoni, Institute
f Medical Statistics and Biometry, University of Milan,
taly.
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Volume 56, Number 6 Gresele et al 1628.e3Supplemental Table I. Demographic characteristics of the subpopulation of patients for which IMT measurements
were available (IMT yes) vs all the remaining study population (IMT no)
Variable IMT No IMT Yes All Patients P value
Age, years
Mean  SD (N) 66.918.44 (259) 66.018.9 (183) 66.538.63 (442) .2797
Median (min-max) 68 (34-81) 68 (39-79) 68 (34-81)
Weight (kg)
Mean  SD (N) 75.9212.43 (259) 75.0712 (183) 75.5712.25 (442) .4712
Median (min-max) 74 (48-114) 75 (50-110) 75 (48-114)
Height (cm)
Mean  SD (N) 168.327.6 (259) 168.478.24 (183) 168.387.86 (442) .8402
Median (min-max) 168 (145-188) 170 (140-187) 168 (140-188)
Alcohol (units/daily)
Mean  SD (N) 1.281.5 (259) 1.531.57 (183) 1.381.54 (442) .0892
Median (min-max) 1 (0-10) 1 (0-10) 1 (0-10)
Coffee/tea (units/daily)
Mean  SD (N) 1.961.62 (258) 2.122.01 (183) 2.021.79 (441) .3469
Median (min-max) 2 (0-10) 2 (0-20) 2 (0-20)
Cigarettes (N/daily)
Mean  SD (N) 5.89.63 (258) 6.619.94 (182) 6.149.76 (440) .3932
Median (min-max) 0 (0-60) 0 (0-40) 0 (0-60)
Basal ACD (minutes)
Mean  SD (N) 5.250.52 (259) 5.210.53 (183) 5.230.53 (442) .4979
Median (min-max) 5.25 (3.96-6.2) 5.19 (4.06-6.19) 5.21 (3.96-6.2)
Basal ICD (minutes)
Mean  SD (N) 4.750.53 (259) 4.70.55 (183) 4.730.53 (442) .3079
Median (min-max) 4.66 (3.42-6.03) 4.61 (3.91-6.03) 4.65 (3.42-6.03)
Race
White/Caucasian 100 (259/259) 100 (183/183) 100 (442/442) —
Gender (M/F)
Female 21.2 (55/259) 20.2 (37/183) 20.8 (92/442) .7953
Male 78.8 (204/259) 79.8 (146/183) 79.2 (350/442)
ACD, Absolute claudication distance; ICD, initial claudication distance; IMT, intima-media thickness; SD, standard deviation.
No significant differences were detected between the two populations for any of the assessed variables.
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ICD10 term NCX 4016 800 mg bid Placebo 800 mg bid
Number (%) of patients with at least 1 adverse event 90 (40.72%) 69 (31.22%)
Diarrhea 25 (11.31%) 5 (2.26%)
Low back pain 5 (2.26%) 5 (2.26%)
Fever 4 (1.81%) 1 (0.45%)
Gastralgia 4 (1.81%) 2 (0.9%)
Influenza 3 (1.36%) 1 (0.45%)
Acute myocardial infarction (not specified) 3 (1.36%) 1 (0.45%)
Nausea and vomiting 3 (1.36%) 0 (0%)
Oliguria 3 (1.36%) 0 (0%)
Oral burning 3 (1.36%) 0 (0%)
Sciatic pain 3 (1.36%) 1 (0.45%)
Anxiety 2 (0.9%) 0 (0%)
Arthritis 2 (0.9%) 0 (0%)
Cataract (not specified) 2 (0.9%) 1 (0.45%)
Claudicatio intermittent 2 (0.9%) 2 (0.9%)
Deep venous thrombosis 2 (0.9%) 0 (0%)
Dyspepsia 2 (0.9%) 3 (1.36%)
Hypertension 2 (0.9%) 2 (0.9%)
Itching (not specified) 2 (0.9%) 0 (0%)
Meteorism 2 (0.9%) 0 (0%)
Osteoporosis 2 (0.9%) 1 (0.45%)
Pyrosis 2 (0.9%) 1 (0.45%)
Surgery prophilaxis 2 (0.9%) 0 (0%)
Thrombophlebitis 2 (0.9%) 0 (0%)
Vertigo 2 (0.9%) 0 (0%)
Abscess perianal 1 (0.45%) 0 (0%)
Accidental cut on scalps skin 1 (0.45%) 0 (0%)
Acute pancreatitis 1 (0.45%) 0 (0%)
Acute pharingitis (not specified) 1 (0.45%) 0 (0%)
Acute tendinitis 1 (0.45%) 0 (0%)
Allergy 1 (0.45%) 0 (0%)
Ankle distorsion 1 (0.45%) 0 (0%)
Arthrosis (not specified) 1 (0.45%) 0 (0%)
Ascites 1 (0.45%) 0 (0%)
Asthma 1 (0.45%) 0 (0%)
Atrial fibrillation and atrial flutter 1 (0.45%) 1 (0.45%)
Bronchitis 1 (0.45%) 4 (1.81%)
Bronchospasm 1 (0.45%) 0 (0%)
Cerebral infarction (not specified) 1 (0.45%) 0 (0%)
Cervical trauma due to a car incident 1 (0.45%) 0 (0%)
Cervicoalgia 1 (0.45%) 1 (0.45%)
Chronic sclerosante hepatopathy 1 (0.45%) 0 (0%)
Colon diverticulosis 1 (0.45%) 1 (0.45%)
Constipation 1 (0.45%) 0 (0%)
Cough 1 (0.45%) 0 (0%)
CPK increase 1 (0.45%) 0 (0%)
Critical ischemia on the contralateral leg 1 (0.45%) 0 (0%)
Cystitis 1 (0.45%) 1 (0.45%)
Dental implantation 1 (0.45%) 0 (0%)
Depression 1 (0.45%) 1 (0.45%)
Dermatitis 1 (0.45%) 0 (0%)
Diabetes 1 (0.45%) 1 (0.45%)
Diarrhea and gastroenteritis of suspected infective origin 1 (0.45%) 0 (0%)
Dyslipidemia 1 (0.45%) 0 (0%)
Dyspnea 1 (0.45%) 0 (0%)
Erythema 1 (0.45%) 0 (0%)
Flushing 1 (0.45%) 0 (0%)
Gastritis (not specified) 1 (0.45%) 0 (0%)
Gastrointestinal hemorrhage (not specified) 1 (0.45%) 0 (0%)
Hemorrhoids 1 (0.45%) 0 (0%)
Herpes zoster 1 (0.45%) 1 (0.45%)
High AST/ALT level 1 (0.45%) 0 (0%)
High GGT level - suspected alchol abuse 1 (0.45%) 0 (0%)
Hyperuricemia 1 (0.45%) 4 (1.81%)
Infection wound foot 1 (0.45%) 0 (0%)
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ICD10 term NCX 4016 800 mg bid Placebo 800 mg bid
Laryngitis 1 (0.45%) 0 (0%)
Limb pain 1 (0.45%) 5 (2.26%)
Liver function test increased 1 (0.45%) 1 (0.45%)
Liver steatosis 1 (0.45%) 0 (0%)
Migratory arthritis 1 (0.45%) 0 (0%)
Periarthritis shoulder 1 (0.45%) 0 (0%)
Pulmonary hypertension 1 (0.45%) 0 (0%)
Renal colic 1 (0.45%) 0 (0%)
Rhinitis vasomotor 1 (0.45%) 0 (0%)
Supraventricolar tachycardia 1 (0.45%) 0 (0%)
Syncope 1 (0.45%) 3 (1.36%)
Teleangectasia 1 (0.45%) 0 (0%)
Thoracic pain (not specified) 1 (0.45%) 1 (0.45%)
Thyroid nodule 1 (0.45%) 0 (0%)
Tooth extraction 1 (0.45%) 1 (0.45%)
Tooth fracture 1 (0.45%) 0 (0%)
Torticollis 1 (0.45%) 1 (0.45%)
Urinary tract infection 1 (0.45%) 0 (0%)
Ustion 1 (0.45%) 0 (0%)
Veins varicose without inflammation or ulcer of lower limbs 1 (0.45%) 0 (0%)
Wound foot 1 (0.45%) 0 (0%)
Acute pulmonary edema 0 (0%) 1 (0.45%)
Aortic murmure 0 (0%) 2 (0.9%)
Atherosclerotic cardiopathy 0 (0%) 1 (0.45%)
Bladder papilloma 0 (0%) 1 (0.45%)
Bradycardia (not specified) 0 (0%) 1 (0.45%)
Cerebral subarachnoid hemorrhage 0 (0%) 1 (0.45%)
Cramps muscle 0 (0%) 1 (0.45%)
Dental abscess 0 (0%) 1 (0.45%)
Epistaxis 0 (0%) 1 (0.45%)
Epithelioma DX back 0 (0%) 1 (0.45%)
Erysipelas 0 (0%) 1 (0.45%)
Foot trauma 0 (0%) 1 (0.45%)
Gastroesophageal reflux disease 0 (0%) 5 (2.26%)
Gastrointestinal problems 0 (0%) 1 (0.45%)
Gouty arthritis 0 (0%) 1 (0.45%)
Hair loss 0 (0%) 1 (0.45%)
Headache 0 (0%) 2 (0.9%)
Hematuria 0 (0%) 1 (0.45%)
Inflammation anal 0 (0%) 1 (0.45%)
Intestinal infection due to Campylobacter J - hypotension -
lipothymia - multiple fractures at left hand 0 (0%) 1 (0.45%)
Left iliac murmure 0 (0%) 1 (0.45%)
Lymphedema left leg 0 (0%) 1 (0.45%)
Malleolar edema 0 (0%) 2 (0.9%)
Other wrist and hand fracture (not specified) 0 (0%) 2 (0.9%)
Phlebitis and thrombophlebitis of the lower limbs 0 (0%) 1 (0.45%)
Pink spot at the thorax 0 (0%) 1 (0.45%)
Rib fracture 0 (0%) 1 (0.45%)
Stomach perforation 0 (0%) 1 (0.45%)
Swelling generalized 0 (0%) 1 (0.45%)
Tooth ache 0 (0%) 1 (0.45%)
Transient ischemic attack 0 (0%) 1 (0.45%)
Trophic lesion right foot 0 (0%) 1 (0.45%)
Umbilical hernia 0 (0%) 1 (0.45%)ALT, Alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.
